Fig. 2From: NKTR-102 Efficacy versus irinotecan in a mouse model of brain metastases of breast cancerPlasma and tumor concentration-time profiles of irinotecan and active metabolite SN38 after IV bolus administration of NKTR-102 (a and b) or irinotecan (c and d) to NU/NU mice with established, orthotopic MDA-MB-231Br brain tumors. Symbols represent individual concentrations, solid line represents mean concentrations (n = 5 per time point)Back to article page